Floatz logo

Docetaxel

Inflammatory Breast Carcinoma

Association Tunisienne de lutte Contre le CancerSmall moleculePhase 3Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

25 Active assets in the Inflammatory Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Trastuzumab
Hoffmann-La Roche
Phase 3BBB
Carboplatin
Northwestern University
Phase 3BBB
Cyclophosphamide
Northwestern University
Phase 3BBB
Pertuzumab
Hoffmann-La Roche
Phase 3BBB
Epirubicin
Northwestern University
Phase 3BB

View all 49 →

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmActive
BBB
Indicative · Phase 4
73 / 100
View asset →
pancreatic adenocarcinomaActive
BBB
Indicative · Phase 2
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative · Phase 2
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →